source
- Beren Therapeutics secures FDA approval for Lembaz to treat infantile-onset Niemann-Pick disease type CBeren Therapeutics announced that the U.S. Food and Drug Administration has approved its drug Lembaz for the treatment of infantile‑onset Niemann‑Pick disease type C, a rare and severe pediatric co…
- FDA rejects ivonescimab for lung cancer; J&J to acquire Ollin Biosciences for up to $3.3B, Senate votes on FDA commissionerThe FDA has denied the application for ivonescimab as a treatment for lung cancer, halting its development for that indication. Johnson & Johnson announced a deal to purchase Ollin Biosciences, a…